In yet another example of the animal spirits
related to any company even mentioning coronavirus, ultra-thinly traded
nano cap Daxor (NYSEMKT:DXR) is up 63% premarket, albeit on only 25K shares, in reaction to its announced “engagement”
with hospitals and government agencies regarding the use of its blood
volume analyzer, BVA-100, in critically ill COVID-19 patients.
It says a clinical trial showed that the use of
the device reduced mortality by as much as 66% in patients suffering
from respiratory distress and septic shock, adding that it has an
inventory of product “ready for deployment.”
https://seekingalpha.com/news/3547412-daxor-up-86-on-coronavirus-news
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.